Evaluation of [125I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry

Cancer Sci. 2011 Nov;102(11):2090-6. doi: 10.1111/j.1349-7006.2011.02057.x. Epub 2011 Sep 15.

Abstract

To image hypoxia-inducible factor-1 (HIF-1)-active tumors, we previously developed a chimeric protein probe ([(123/125) I]IPOS) that is degraded in the same manner as HIF-1α under normoxic conditions. In the present study, we aim to show that the accumulation of radioiodinated POS reflects the expression of HIF-1. In vivo single-photon emission computed tomography (SPECT)/X-ray CT (CT) imaging, autoradiography, and double-fluorescent immunostaining for HIF-1α and pimonidazole (PIMO) were carried out 24 h after the injection of [(125) I]IPOS. Tumor metabolite analysis was also carried out. A tumor was clearly visualized by multi-pinhole, high-resolution SPECT/CT imaging with [(125) I]IPOS. The obtained images were in accordance with the corresponding autoradiograms and with the results of ex vivo biodistribution. A metabolite analysis revealed that 77% of the radioactivity was eluted in the macromolecular fraction, suggesting that the radioactivity mainly existed as [(125) I]IPOS in the tumors. Immunohistochemistry revealed that the HIF-1α-positive areas and PIMO-positive areas were not always identical, only some of the regions were positive for both markers. The areas showing [(125) I]IPOS accumulation were positively and significantly correlated with the HIF-1α-positive areas (R = 0.75, P < 0.0001). The correlation coefficient between [(125) I]IPOS-accumulated areas and HIF-1α-positive areas was significantly greater than that between the [(125) I]IPOS-accumulated areas and the PIMO-positive areas (P < 0.01). These findings indicate that [(125) I]IPOS accumulation reflects HIF-1 expression. Thus, [(123/125) I]IPOS can serve as a useful probe for the molecular imaging of HIF-1-active tumors.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoradiography*
  • Biotin / analogs & derivatives*
  • Biotin / pharmacokinetics
  • Female
  • Fluorescent Antibody Technique, Direct*
  • Hypoxia-Inducible Factor 1, alpha Subunit / analysis*
  • Iodine Radioisotopes* / pharmacokinetics
  • Mammary Neoplasms, Experimental / diagnostic imaging*
  • Mammary Neoplasms, Experimental / metabolism
  • Mice
  • Mice, Inbred C3H
  • Neoplasm Proteins / analysis*
  • Nitroimidazoles / analysis
  • Radiopharmaceuticals* / pharmacokinetics
  • Recombinant Fusion Proteins* / pharmacokinetics
  • Tissue Distribution
  • Tomography, Emission-Computed, Single-Photon / methods*
  • Tomography, X-Ray Computed*

Substances

  • 3-(iodobenzoyl)norbiotinamide-PTD-ODD-SAV fusion protein
  • Hif1a protein, mouse
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Iodine Radioisotopes
  • Neoplasm Proteins
  • Nitroimidazoles
  • Radiopharmaceuticals
  • Recombinant Fusion Proteins
  • pimonidazole
  • Biotin